Price T Rowe Associates Inc Immuneering Corp Transaction History
Price T Rowe Associates Inc
- $869 Billion
- Q3 2024
A detailed history of Price T Rowe Associates Inc transactions in Immuneering Corp stock. As of the latest transaction made, Price T Rowe Associates Inc holds 810,127 shares of IMRX stock, worth $1.62 Million. This represents 0.0% of its overall portfolio holdings.
Number of Shares
810,127
Previous 859,374
5.73%
Holding current value
$1.62 Million
Previous $1.1 Million
83.45%
% of portfolio
0.0%
Previous 0.0%
Shares
13 transactions
Others Institutions Holding IMRX
# of Institutions
41Shares Held
4.64MCall Options Held
0Put Options Held
0-
Vanguard Group Inc Valley Forge, PA1.07MShares$2.14 Million0.0% of portfolio
-
Black Rock Inc. New York, NY533KShares$1.07 Million0.0% of portfolio
-
Morgan Stanley New York, NY449KShares$898,6220.0% of portfolio
-
Israel Englander Millennium Management LLC | New York, Ny246KShares$492,5400.0% of portfolio
-
Geode Capital Management, LLC Boston, MA210KShares$419,2820.0% of portfolio
About Immuneering Corp
- Ticker IMRX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 26,392,300
- Market Cap $52.8M
- Description
- Immuneering Corporation, a biopharmaceutical company, focuses on the oncology and neuroscience product candidates. Its lead product candidates include IMM-1-104, a dual-MEK inhibitor to treat patients with cancer, including pancreatic, melanoma, colorectal, and non-small cell lung cancer caused by mutations of RAS and/or RAF; and IMM-6-415 to tr...